Diagnostyka

Diagnostyka S.A. Announces Extraordinary General Meeting and Key Resolutions

Diagnostyka S.A., headquartered in Kraków, has announced the convening of an Extraordinary General Meeting (EGM) scheduled for August 31, 2026. The agenda, disclosed in the company’s recent regulatory filing, includes significant resolutions that have been positively reviewed by the Supervisory Board.

Key resolutions to be addressed during the EGM include:

• The appointment of Jakub Tatak as Vice President of the Management Board.
• The merger of Diagnostyka S.A. with its subsidiary, Diagnostyka Digital Hub Sp. z o.o., based in Kraków.

The Supervisory Board unanimously approved these resolutions during a vote conducted on July 29-30, 2026, with all eight members in favor. The resolutions align with the company’s adherence to the "Best Practices of WSE Listed Companies 2021" guidelines.

Relevance: This development is significant for Diagnostyka S.A. as it reflects the company’s ongoing efforts to strengthen its leadership team and streamline operations through strategic mergers, supporting its growth strategy and operational efficiency.

Diagnostyka S.A. Announces Extraordinary General Meeting to Address Key Strategic Decisions

Diagnostyka S.A., a leading Polish healthcare diagnostics company, has scheduled an Extraordinary General Meeting (EGM) for August 31, 2026, at 2:00 PM in Kraków. The meeting will take place at the Aquarius building, located at ul. Życzkowskiego 18. The agenda includes several critical resolutions aimed at strengthening the company's strategic direction and operational efficiency.

The key points on the agenda are:

• Appointment of Jakub Tatak as Vice President of the Management Board. Tatak, a seasoned finance executive with over 25 years of experience, including nearly two decades in the healthcare sector, is expected to enhance the company's financial strategy and governance.
• Approval of the merger with Diagnostyka Digital Hub, a wholly-owned subsidiary specializing in IT and digital solutions. The merger aims to integrate IT operations into the parent company, streamlining processes and enhancing technological capabilities.

Shareholders eligible to participate in the EGM must hold at least one share of Diagnostyka S.A. as of August 15, 2026, and follow the registration procedures outlined by the company. Voting can be conducted in person, via proxy, or through correspondence, with detailed instructions available on the company’s official website.

The proposed resolutions are expected to bolster Diagnostyka S.A.'s position as a market leader in healthcare diagnostics, aligning with its strategy of growth through acquisitions, infrastructure expansion, and technological advancements.

Relevance to Diagnostyka S.A.: The EGM reflects Diagnostyka S.A.'s commitment to strengthening its leadership team and optimizing its operational structure, which are critical to sustaining its growth trajectory and competitive edge in the healthcare diagnostics sector.

Diagnostyka S.A. Reports Strong Q1 2026 Financial Performance Amid Strategic Growth and Market Expansion

Kraków, Poland – May 28, 2026: Diagnostyka S.A., a leading Polish healthcare diagnostics group, has reported robust financial results for the first quarter of 2026, driven by strategic acquisitions, organic growth, and increased demand for diagnostic services. The company achieved a 14.6% year-on-year (YoY) increase in operational revenue, reaching PLN 681.6 million, while net profit attributable to shareholders rose by 13.3% YoY to PLN 82.6 million. The Group also recorded a 1.2% YoY increase in test volumes, totaling 45.8 million tests, alongside a 16.5% rise in the average price of diagnostic tests.

Key developments in Q1 2026 included the acquisition of 61% of Skamed Rezonans (diagnostic imaging), 75% of PP Diagnostyka Sp. z o.o. (diagnostic imaging), and 100% of LAB-AD and Instytut Mikroekologii (both in laboratory diagnostics). Additionally, Diagnostyka acquired several organized parts of enterprises (ZCPs) to strengthen its market position in laboratory diagnostics. The company also continued its participation in national health programs, including "Moje Zdrowie" and the Cervical Cancer Prevention Program, further solidifying its role in Poland's healthcare system.

Diagnostyka invested significantly in infrastructure, including the development of modern laboratories in Gdynia and Gliwice, and launched a new integrated ERP system, SAP, to enhance operational efficiency. The company also announced a dividend payout of PLN 4.40 per share, totaling PLN 148.5 million, approved by its General Meeting on May 25, 2026.

Despite facing challenges such as rising operational costs and wage pressures, Diagnostyka remains optimistic about its growth prospects, driven by market trends such as increasing demand for diagnostic services, aging demographics, and advancements in automation and artificial intelligence.

Relevance to Diagnostyka S.A.: The article highlights Diagnostyka S.A.'s strong financial performance, strategic acquisitions, and market expansion, aligning with its business model of growth through acquisitions, infrastructure development, and increased demand for diagnostic services.